Background: Chronic continuous abdominal pain (CCAP) is characteristic of centrally
| INTRODUC TI ON
Significant advances have been made in understanding, classifying and diagnosing common episodic painful functional gastrointestinal disorders (FGIDs) such as irritable bowel syndrome (IBS). 1 However, less common chronic continuous abdominal pain (CCAP), with no clear underlying structural or metabolic cause, remains as a challenging clinical entity for which very little is known to guide practice. Such patients may present repeatedly to secondary and tertiary services, with significant psychological co-morbidity, multiple repeated negative investigations and heavy socioeconomic costs including healthcare utilisation and the burden of loss of working days due to illness. [2] [3] [4] [5] [6] These patients may be subjected to futile or counter-productive treatments including opioid analgesia. 7 Indeed, the detrimental effects of opioids in this setting are increasingly being recognised and include nausea, vomiting, constipation and the development of opioid-induced hyperalgesia. 2, 8, 9 Despite the significant severity and morbidity attributed to CCAP, there remain substantial gaps in the clinical evidence base in several key areas:
Firstly, there is very limited published cohort specific data for the clinical diagnostic and putative pathophysiological features in CCAP patients. In order to distinguish CCAP from episodic painful functional gut disorders such as IBS, the "centrally mediated abdominal pain syndrome" (CAPS) construct has been formulated. This is defined by Rome IV diagnostic criteria as CCAP that is minimally related to the physiological events of eating, defecation and menses and results in a loss of day-to-day functioning. 2 However, direct clinical evidence of how frequently these diagnostic criteria are present in a "real world" CCAP cohort is currently lacking.
Furthermore the nature of CCAP pathophysiological attribution and treatment recommendations, including a putative role of "neuropathic" pain (ie pain arising from peripheral/central nerve dysfunction as opposed to normal "nociceptive" pain provoked by tissue damage) remains speculative and derivative. 10 In CAPS, it is notable that the clinical features, postulated pathophysiology of central sensitisation 11, 12 and recommended centrally acting neuromodulator therapy significantly overlap that of neuropathic pain 13 and evidence is partially extrapolated from studies in other, nongastrointestinal, painful neuropathic conditions including fibromyalgia, chronic back pain and headache. 2, 14, 15 Moreover, key clinical diagnostic features of neuropathic pain, including allodynia (a nonpainful stimulus evoking pain sensation) and hyperalgesia (pain experienced as more painful for a given stimulus), have recently been defined by a consensus study using a Delphi approach. 13 Additionally, lower abdominal cutaneous electrical pain thresholds as a quantitative measure of allodynia have been shown to be predictive of response to centrally acting neuromodulators in CCAP secondary to chronic pancreatitis. 16 As an alternative to electrical pain thresholds, mechanical dynamic allodynia is a more readily elicited physical sign in the clinic setting using simple gentle brush strokes over the skin, and is attributed to central sensitisation in patients with neuropathic pain. [17] [18] [19] However, the prevalence of neuropathic pain diagnostic features and the objective sign of mechanical dynamic allodynia in CCAP are unknown.
Secondly, another major gap in the literature concerns more detailed information as to the possible iatrogenic impacts of opioid use and of surgical interventions on clinical outcomes in CCAP.
Finally, a third major gap in the CCAP literature is regarding pharmacological treatment. Whilst there is increasing interest in the use of gut-brain neuromodulators for treating functional gastrointestinal pain, 14, 15 there remains a paucity of "real world" cohort-specific data to support their use in patients with CCAP. Given the relative rarity of the diagnosis compared to the more prevalent episodic painful functional gastrointestinal disorders, it is unlikely that a randomised controlled trial will ever be performed. Therefore there is an urgent need for "real world" data evaluating outcomes from these drugs in patients with CCAP. Interestingly, linaclotide is not currently considered to be a gut-brain neuromodulator, but has been shown to have some emerging evidence for visceral analgesic effects, possibly through neuroenteric mechanisms, 20, 21 but its effects in CCAP are currently unknown and were therefore evaluated in this study.
This study has therefore sought to address these evidence gaps by reviewing a large CCAP patient dataset. In particular, this study had three main aims;
1.
To elicit clinical diagnostic and putative pathophysiological features in CCAP patients, vis-à-vis both current Rome IV Centrally Mediated and also Delphi consensus Neuropathic Pain criteria.
2.
To solicit any iatrogenic effects of opioids and surgery in CCAP patients.
3.
To determine the responses to drug treatments in CCAP patients.
| MATERIAL S AND ME THODS
We conducted a retrospective review of the electronic medical records of all patients who attended a regional tertiary functional gastrointestinal clinic in the North West of England between 1 January 2009 and 31 May 2016. Ethics approval was not required for this study, since this was a service evaluation of existing practice compared with Rome guidelines.
| Definition of CCAP
All CCAP patients included met the same chronic continuous pain definition as used in Rome IV-that the pain should be "continuous or nearly continuous" "with pain occurring more or less every day" and should have been present for at least the preceding 3 months and onset at least 6 months before diagnosis. Questionnaires were not used, but all patients were asked the same questions in clinic as to the frequency and duration of their pain. These were documented in the patients' case notes and retrospectively elicited from all patients' charts.
| Patient population
Patients with unexplained CCAP were identified from a prospectively maintained database of tertiary clinic referrals. Patients whose symptoms were attributable to an alternative active primary structural or metabolic diagnosis were excluded. In line with Rome IV CAPS criteria, patients with previous surgery, adhesions or inactive organic diagnosis were included. Patients with the anterior cutaneous nerve entrapment syndrome were excluded on the basis of a positive Carnett's sign and very focal cutaneous allodynia along the rectus sheath. It was recorded as to whether the patient had indicated that the drug had helped their pain, whether it had not helped their pain and whether they had needed to stop due to intolerance of side effects.
| Data collection
These were standard questions asked about drug efficacy and tolerance to all patients in clinic.
All patients initiated on neuromodulators received the same advice, together with their GP, to start at a low dose and up-titrate according to tolerance and response and to use for a minimum of 2 to 3 months before concluding there was no effect.
Whilst we were unable to systematically capture the data on dose and duration, the standard dosing advice for these drugs from the clinic was as follows:
For amitriptyline to start at 20 mg nocte and up-titrate in 10 mg increments per week to a dose between 30-50 mg according to tolerance and response. Higher doses up to 100 mg nocte were permitted. If limiting daytime somnolence side effects were encountered then the recommendation was made to switch to an equivalent dose of nortriptyline.
For duloxetine 30 mg once daily was recommended as the starting dose, up-titrating to 30 mg twice daily if required.
For gabapentin, a 300 mg three times daily starting dose was recommended, up-titrating in 100 mg three times daily increments per week according to tolerance and response to a maximum dose of 1.2 g three times daily. It was recommended that most patients would likely need between 600 mg and 900 mg three times daily to get some meaningful response. If side effects were encountered at the 300 mg three times daily starting dose, then it was suggested to re-start at 100 mg three times daily and up-titrate.
For pregabalin it was recommended to start at 75 mg twice daily and up-titrate in 75 mg twice daily weekly increments to a maximum dose of 300 mg twice daily.
Data were also collected on investigations performed and details of engagement with nutrition, chronic pain and psychology services.
Background pain scores were recorded which had been physician recorded from verbal patient report, of the level of constant background pain, with the patients given a reference range by the physician of zero (no pain) to 10 (worst pain ever).
| Outcome measures

| Diagnostic criteria
Case notes were reviewed retrospectively, by investigators not involved in the patients care, for the following diagnostic criteria:
Rome IV the CAPS criteria and the neuropathic pain criteria described by Searle et al 13 ( Table 1 ).
| Definition and examination for "abdominal allodynia"
"Allodynia" is defined as a nonpainful innocuous stimulus evoking a painful sensation. It is a characteristic feature and biomarker of neuropathic pain (ie pain due to nerve dysfunction). There are different types of allodynia including mechanical dynamic allodynia, mechanical static allodynia, cold allodynia and heat allodynia that reflect different types of nerve dysfunction. 17 In particular, dynamic mechanical allodynia on physical examination refers to gentle/light brush strokes over the skin evoking pain (using either a brush or cotton swab), which is due to the central sensitisation component of neuropathic pain. 17 This has previously been used for abdominal and pelvic skin examination. 18 Derivative from the well established and validated brush or cotton swab light pressure moving stimulus on the skin, mechanical dynamic allodynia was assessed for in all patients by clinician fingertip brush strokes in unaffected compared with maximally affected abdominal cutaneous pain areas. 17, 18 This sign may be missed using the traditional "light pressure" palpation abdominal examination technique. The patient was first asked to indicate an area of abdominal skin that was not painful or felt normal. Since the term "cutaneous abdominal mechanical dynamic allodynia" is overly cumbersome, it will be referred to elsewhere in the paper as the short form "abdominal allodynia."
We have also occasionally referred to visceral allodynia. This is defined as painful sensation due to nerve dysfunction arising from the lumenal viscera (as opposed to cutaneous) provoked by innocuous physiological events or stimuli. This was not directly tested for during this study as there is no standardised clinically available test for this and is confined to research settings using invasive methodologies. Within group analyses were then made for CAPS and non-CAPS patients independently, comparing characteristics of those patients who did and did not tolerate specific prescribed medication. These analyses were limited to cases where each medication or combination of medications was prescribed.
| Statistical analysis
In all analyses above, for continuous variables normality of distribution was determined by Shapiro-Wilk test. Normally distributed descriptive data are presented as mean ± standard deviation (SD), and nonnormally distributed data as median (minimum, maximum).
Statistical comparisons between normally distributed variables were made using unpaired t tests. Statistical comparisons between nonnormally distributed variables were made using Mann-Whitney U test.
To compare the association of nonpharmacotherapeutic variables with CCAP symptom burden, univariate binary logistic regression was used. Dependent variables were the presence of abdominal allodynia and any surgery after CCAP diagnosis, independent variables are those listed above. Analyses were performed for CAPS and non-CAPS patients separately.
A similar comparison was performed for CCAP patients who gave a history of concomitant (quiescent) structural gastrointestinal disease and those who did not and for CCAP patients who gave a history of surgery prior to CCAP onset and those who did not.
For between group comparison of clinical characteristics between patients on opioid therapy, patients previously on opioid therapy and opioid naive patients, univariate binary logistic regression was performed with opioid naïve patients as the reference group.
Odds ratios were generated for the presence of each symptom or clinical outcome in patients on or previously on opioids compared to opioid naïve patients.
For all analyses, statistically significant results are presented as P < 0.05 and results that remained significant after Bonferroni correction are highlighted as such, the α values after correction being specific to each analysis. All analyses were performed using the statistical software package SPSS v22.0, IBM.
| RE SULTS
| Clinical characteristics
One hundred and three patients with CCAP (mean age 40 ± 14;
88/103 (85%) female) were included. At first presentation to the clinic, only 18/103 (17%) had never used opioids (opioid naïve), 13/103 (13%) had previously used opioids but were not currently on opioids and 72/103 (70%) were currently using opioids. Poor opioid response, n (%) 61 (59) Shooting, n (%) 13 (13) Burning, n (%) 12 (12) Dysaesthesia, n (%) 9 (9) Hyperalgesia, n (%) 7 (7) Good response to neuropathic agents, n (%) 35 (34) Background pain scores were available for 59/103 patients based on a verbally solicited analogue score, given anchors by the clinician of 0 (no pain) to 10 (worst pain). The mean background pain score was 4.8 ± 1.7.
| Rome IV centrally mediated diagnostic criteria
Out of 103, 52 patients (50%) were fully satisfied all of the Rome IV CAPS criteria (Table 1) . Of the 51/103 (50%) who did not fulfil all Rome IV CAPS criteria (non-CAPS), 50/51 reported that their constant background pain was frequently exacerbated by "physiological events" (post-prandial (n = 36), on defecation (n = 8), preceding defecation (n = 5) during menstruation (n = 2), with some patients reporting more than one type of physiological trigger for exacerbation and two also reporting no loss of function) and one reported no loss of function without physiological event exacerbation.
A comparison was made between CCAP patients who fulfilled all Rome IV CAPS criteria and those (non-CAPS) who did not. There were no significant differences between these two groups in clinical characteristics (Table 2) ; drugs used (Table 3) ; drug effectiveness (Table 3) or tolerance (Table 3) . Furthermore, there were no significant differences between the two groups with respect to effects of the presence of abdominal allodynia, pain scores or number of operations after diagnosis on the different pharmacotherapy regimes (Tables S1-S3 ). There were also no differences between the two groups with respect to nonpharmacotherapy parameters associated with abdominal allodynia (Table S4 ).
| Neuropathic pain criteria
Data were available for four of the neuropathic pain criteria (spontaneous, difficult to manage, abdominal allodynia, poor response to opioids) in all patients. Two neuropathic features were present in almost all patients ("spontaneous" pain 100/103 (97%), "difficult to manage" 102/103 (99%), Table 1 ). Notably, 83/103 (81%) had evidence of abdominal allodynia on physical examination. Another important neuropathic feature "poor response to opioids," was found in the majority of those who had taken opioids (61/81, 72%).
| Impact of opioids
Intriguingly, the presence of abdominal allodynia on physical examination was highly significantly associated with current opioid use (P = 0.003, Table 4 ). There was a trend for previous opioid use to be associated with previous surgery, and both previous and current opioid use to be associated with bloating symptoms, but these did not retain significance after Bonferroni correction for multiple comparisons. most prevalent diagnoses. Other organic co-morbidities included endometriosis (n = 5), gallstones (n = 4), haemorrhoids (n = 3), hernia (n = 2), chronic pancreatitis (n = 2) and peripheral neuropathy (n = 2).
In all patients, the referring clinician had indicated that the concomitant organic diagnosis was not active and did not explain the chronic severe pain. Analyses were performed using chi square test on an intention to treat basis. Patients whose symptoms improved after using each drug were compared to those who either did not tolerate the drug or did not improve after its use. Patients who had never been prescribed the drug were excluded. CAPS, centrally mediated abdominal pain syndrome; N & V, nausea and vomiting; NM, neuromodulatory drug; L, linaclotide. *Statistically significant at P < 0.05 (values did not retain significance after Bonferroni correction).
TA B L
There were no significant differences between CCAP patients who gave a history of concomitant (quiescent) gastrointestinal diseases and those who did not (Table 5 ).
| Surgical interventions performed in patients with CCAP
Seventy patients (68%), had a background of previous abdominal surgery and 27% of these patients identified surgical intervention as an initiating trigger to CCAP. Overall, the most common surgical interventions were; appendicectomy (n = 26/70, 37%), cholecystectomy (n = 15/70, 21%) and hysterectomy (n = 19/70, 27%). Histology was not available from the referral centres in the majority of patients' case records.
Interestingly, the majority of patients who had surgical inter- There was a highly significant association between CCAP patients having had surgery prior to CCAP onset going on to have more operations post CCAP onset than CCAP patients who had never had a previous operation (P < 0.001). There were otherwise no significant differences between CCAP patients with or without previous surgery (Table 5 ). Bonferroni correction for multiple comparisons (Table 6 ).
| Clinical response to centrally acting neuromodulators
Patients with known outcomes were stratified into two groups according to the number of drugs they had taken concurrently. Eight patients were excluded as data regarding the relative time periods of the drug prescribing were not available. Combination therapy with >1 centrally acting neuromodulator (n = 12/14, 86% response) was superior to centrally acting neuromodulator monotherapy (n = 10/19, 53% response,), P = 0.007 (Table 7) .
| D ISCUSS I ON
In this largest cohort-specific analysis of the diagnosis and management of CCAP to date, our data are the first to elicit the clinical N & V, nausea and vomiting. *Statistically significant at P < 0.05 (value did not retain significance after Bonferroni correction). **Retained significance after Bonferroni correction. Analyses were performed using binary logistic regression with amitriptyline as the reference drug CI, confidence intervals; OR, odd's ratio for effectiveness or tolerance compared to reference drug. *statistically significant at P < 0.05. **retained significance after Bonferroni correction. $ OR value >1000 likely spurious due to small numbers. In addition to clinical characteristics of CCAP patients, our study also explored iatrogenesis relating to opioids and surgery.
TA B L
Importantly, almost two thirds of patients who had used opioids in our study reported a poor response to these medications. Moreover, abdominal allodynia was significantly associated with opioid use, with patients on opioids more likely to exhibit the altered nociceptive behaviour underpinning allodynia. Allodynia in this context therefore may also be a bio-marker for opioid-induced hyperalgesia in the context of a pre-existing neuropathic pain state. This supports the notion that opioids are counterproductively altering pain neurobiology and should be avoided in the management of CCAP.
Increased prevalence of abdominal surgeries in patients with functional gut disorders is well documented, as is the onset of postsurgical neuropathic pain and these findings are mirrored in our CCAP cohort. [23] [24] [25] [26] In particular we have identified that surgery prior to CCAP onset is associated with further surgery post-CCAP onset.
We have also identified that surgical intervention is associated with poor clinical outcomes, and worsening symptoms in a third of patients. Moreover, our data have shown no clinical improvement with adhesiolysis and would support findings from published randomised controlled trials, which suggest avoidance of adhesiolysis unless bowel viability is under threat. 27, 28 It should be recognised that a limitation of this study was that we did not have access to the pathology reports of the surgical specimens from the referring centres.
Finally after exploring clinical characteristics and iatrogenesis in CCAP patients, our study explored response to treatments. In particular, our data lend support to the use of centrally acting neuromodulators in patients with CCAP. Duloxetine appeared to be the most efficacious single agent neuromodulator, whilst neuromodulator combination therapy appeared to be more effective than monotherapy.
Despite the lack of cohort-specific data on clinical efficacy and utility of these agents, current pharmacotherapeutic recommendations for centrally mediated gastrointestinal pain disorders are to use neuromodulatory medications derivatively from evidence in other painful functional gut disorders. 16, [29] [30] [31] Our data thus provide additional clinical evidence to support the recent empirical guidelines on centrally acting neuromodulators and suggest benefit in 53% of patients with monotherapy, increasing to 86% response using augmentation therapy with more than one agent in combination. These "real world" data are particularly important in light of the new recommendations, 14, 15 given that most gastroenterologists have traditionally not been accustomed to nor trained to prescribe these types of medications. in IBS patients, 20 and earlier work in animal models suggesting this may be via neuroenteric mechanisms. 21 Most recently in a study using cortical evoked potentials, linaclotide was found to improve abdominal pain in IBS by modulating afferent nerve signalling pathways to the brain. 32 Our data suggest that it might be considered as an option for patients with CCAP, particularly when chronic constipation is a co-existing feature.
We recognise that there are significant limitations to an uncontrolled retrospective single-centre case series review; however,
given the rarity and difficulties in evidence collation for CCAP patients, we present a number of interesting and important new observations in addition to reinforcing already existing consensus.
Interpretation of the centrally acting neuromodulator data needs to be with caution as prescriber bias cannot be excluded. Furthermore, there may be some degree of patient selection bias in that some patients who did not respond to treatments may be more likely to present for care optimisation than those who did. Additionally, outcome data were not available for all patients that received these medications.
After initial diagnosis of a centrally mediated pain disorder, for many patients the distance of travel involved for this tertiary setting, meant local follow up with their local chronic pain team to review and modify the anti-neuropathic and opioid pain medication was more appropriate. Outcome data for neuromodulator treatment was therefore not available for these. Moreover we were unable to collect dose and duration of treatment data, although all patients received standard advice in these respects, as outlined in the methods section above. Given the apparent rarity of these cases, it will be challenging to embark on any placebo controlled or head-to-head randomised and blinded studies in CCAP. Furthermore, our study did not evaluate the efficacy of psychological 6 or individualised pain management programmes, which would be important in the future given that pain does not respond to drug therapy in a third of patients. Future study of other nondrug interventions therefore, such as neurostimulation devices, 33 may also be valuable for these patients. Other areas of future research include determining whether there are additional genotypic or psychophysiological endophenotype markers for pain vulnerability; and more thorough prospective attempts to elicit other neurobiological signs such as cutaneous dysaesthesia/numbness and visceral allodynia/dysaesthesia.
In conclusion, this large cohort series of CCAP patients has shed light on some of the clinical evidence gaps and found risk factors for both poorer outcomes but also optimised therapy. We believe these findings can help inform future iterations of centrally mediated pain syndrome criteria, as well as clinical decision making to help avoid harm and optimise positive outcomes for this group of patients.
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